Tipifarnib demonstrated promising efficacy in a phase II clinical trial in patients with recurrent and/or metastatic HNSCC with HRAS mutations for whom limited therapeutic options exist (NCT02383927). This evidence concerns the gene HRAS and head and neck squamous cell carcinoma.